tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Kilitch Drugs Approves Rights Issue to Strengthen Capital

Story Highlights
Kilitch Drugs Approves Rights Issue to Strengthen Capital

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Kilitch Drugs (India) Limited ( (IN:KILITCH) ) just unveiled an announcement.

Kilitch Drugs (India) Limited announced the approval and allotment of 13,98,463 equity shares on a rights basis to eligible shareholders at an issue price of Rs. 357 per share. This move, approved by the Board of Directors, is expected to enhance the company’s capital structure and provide additional resources for its operational and strategic initiatives.

More about Kilitch Drugs (India) Limited

Kilitch Drugs (India) Limited operates in the pharmaceutical industry, focusing on the production and distribution of a variety of pharmaceutical products. The company is known for its commitment to quality and innovation in the healthcare sector.

Average Trading Volume: 3,224

Technical Sentiment Signal: Buy

Current Market Cap: 7.08B INR

See more data about KILITCH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1